[HTML][HTML] Immunotherapy in non-small cell lung cancer: Update and new insights
X Mielgo-Rubio, EA Uribelarrea, LQ Cortés… - Journal of clinical and …, 2021 - ncbi.nlm.nih.gov
Background: The treatment of non-small-cell lung carcinoma (NSCLC) has changed
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
Immunotherapy in non-small cell lung cancer: Update and new insights.
X Mielgo-Rubio, EA Uribelarrea, LQ Cortés… - Journal of Clinical …, 2021 - europepmc.org
Background The treatment of non-small-cell lung carcinoma (NSCLC) has changed
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
[PDF][PDF] Immunotherapy in non-small cell lung cancer: Update and new insights
X Mielgo-Rubio, EA Uribelarrea, LQ Cortés… - Journal of Clinical and …, 2021 - jctres.com
Background: The treatment of non-small-cell lung carcinoma (NSCLC) has changed
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
[PDF][PDF] Immunotherapy in non-small cell lung cancer: Update and new insights
X Mielgo-Rubio, EA Uribelarrea… - Journal of Clinical …, 2021 - pdfs.semanticscholar.org
Background: The treatment of non-small-cell lung carcinoma (NSCLC) has changed
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
Immunotherapy in non-small cell lung cancer: Update and new insights
X Mielgo-Rubio, EA Uribelarrea… - Journal of clinical …, 2021 - pubmed.ncbi.nlm.nih.gov
Background The treatment of non-small-cell lung carcinoma (NSCLC) has changed
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
Immunotherapy in non-small cell lung cancer: Update and new insights.
X Mielgo-Rubio, EA Uribelarrea, LQ Cortés… - Journal of Clinical …, 2021 - europepmc.org
Background The treatment of non-small-cell lung carcinoma (NSCLC) has changed
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
Immunotherapy in non-small cell lung cancer: Update and new insights
X Mielgo-Rubio, EA Uribelarrea, LQ Cortés, M Sereno… - 2020 - jctres.com
The minor revision pertains to language polishing. Please inform us if you cannot do this
yourself, find a native speaker who can help, or engage a paid service to contract it to a third …
yourself, find a native speaker who can help, or engage a paid service to contract it to a third …